The Securities Appellate Tribunal has reversed the penalty imposed by market regulator, Sebi, on three public sector entities in the matter of UTI Asset Management Company.
Norway: Lundin Energy announces resource additions of 210 percent of 2020 production
12 Jan 2021
Lundin Energy has announced that as at 31 December 2020, its proved plus probable net reserves (2P reserves) are 671 million barrels of oil equivalent (MMboe) and its proved plus probable plus possible net reserves (3P reserves) are 826 MMboe. 2P reserves plus best estimate net contingent resources (total resource) are 946 MMboe, with a total resource replacement ratio
for 2020 of 210 percent.
Lundin Energy’s 2P reserves as at 31 December 2020 are 670.9 MMboe and reflect a positive revision of 39.3 MMboe. The 3P reserves as at 31 December 2020 are 826.0 MMboe and reflect a positive revision of 30.0 MMboe. The best estimate net contingent resources (2C resources) as at 31 December 2020 are 275.5 MMboe, which is an increase of 90.2 MMboe from year end 2019. The total resource as at 31 December 2020 are 946.4 MMboe, which reflects additions of 129.4 MMboe from year end 2019, including
Securities Appellate Tribunal overturns SEBI penalty on SBI, LIC, Bank of Baroda over UTI MF
SEBI had fined the three entities for holding over 10% stake in UTI MF, which was in violation of SEBI rules
BusinessToday.In | January 12, 2021 | Updated 14:58 IST
The Securities Appellate Tribunal (SAT) has reversed the penalty imposed by the Securities and Exchange Board of India (SEBI) on three entities (Photo- Reuters)
The Securities Appellate Tribunal (SAT) has reversed the penalty imposed by the Securities and Exchange Board of India (SEBI) on State Bank of India (SBI), Bank of Baroda and Life Information Corporation (LIC) on the matter of UTI Asset Management Company (AMC).
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA (Angiotensin II) and XERAVA (Eravacycline) in Europe
Warnings and Precautions
There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
AlgaEnergy and Laboratoire M2 Sign Global Strategic Partnership Agreements for Distribution and Product Development
USA - English
Share this article
Share this article
AlgaEnergy will become exclusive worldwide distributor of Laboratoire M2 biocontrol products and will collaborate with the Quebec company s scientists on new disease-control products for agriculture
MADRID, Spain and SHERBROOKE, QC, Jan. 12, 2021 /PRNewswire/ AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. and a global leader in microalgae biotechnology, has signed global product distribution and product development agreements with Laboratoire M2 Inc., a Quebec-based biotechnology company that develops natural and sustainable disinfectant products, including THYMOX CONTROL® fungicide and bactericide.